Researchers have developed a new methodology that uses artificial intelligence tools to identify and count target viruses ...

In an NBC News story about the reality gap between businesses talking about artificial intelligence (AI) and those that are actually using it, an investment analyst from Oppenheimer said, “There’s not ...

The world population is suffering a lot of genetic diseases. These diseases have been very hard to tackle so far. Fortunately, since a few decades viral vectors and gene therapies became more and more ...

Accurate characterization of large viral vectors is a critical step in developing viral vector-based gene therapies and vaccines for use in cancer immunotherapies, genetic disorders, infectious ...

Researchers have developed a new methodology that uses artificial intelligence (AI) tools to identify and count target viruses more efficiently than previous techniques. The new approach can be used ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.